Contrasting Effects of Adipokines on the Cytokine Production by Primary Human Bronchial Epithelial Cells: Inhibitory Effects of Adiponectin.

adiponectin cytokine human bronchial epithelial cell obesity receptor

Journal

Frontiers in pharmacology
ISSN: 1663-9812
Titre abrégé: Front Pharmacol
Pays: Switzerland
ID NLM: 101548923

Informations de publication

Date de publication:
2020
Historique:
received: 22 08 2019
accepted: 22 01 2020
entrez: 6 3 2020
pubmed: 7 3 2020
medline: 7 3 2020
Statut: epublish

Résumé

Obesity is associated with an elevated risk of respiratory infections and inflammatory lung diseases. The objective was to investigate (i) the effects of adipokines (adiponectin (APN), leptin, chemerin, and visfatin) on the production of cytokines by unstimulated and poly(I:C)- and TNF-α-activated human primary bronchial epithelial cells (hBECs), (ii) the cells' expression of the APN receptors (AdipoR1 and AdipoR2), and (iii) the cells' production of APN. The hBECs were isolated from patients undergoing surgery for lung carcinoma. The cells were then cultured with human recombinant adipokines in the absence or presence of TNF-α or poly(I:C) for 24 h. Supernatant levels of cytokines (IL-6, CCL2, CCL5, CCL20, CXCL1, CXCL8) and APN were measured using ELISAs. The mRNA levels of AdipoR1 and AdipoR2 in hBECs were determined using a real-time quantitative PCR. Of the four adipokines tested, only APN significantly influenced the basal production and the TNF-α poly(I:C)-induced production of cytokines by hBECs. APN (3-30 µg.ml The APN concentrations are abnormally low in obese individuals, and this fall may contribute to the susceptibility to viral lung infections and the severity of these infections in obese individuals.

Sections du résumé

BACKGROUND BACKGROUND
Obesity is associated with an elevated risk of respiratory infections and inflammatory lung diseases. The objective was to investigate (i) the effects of adipokines (adiponectin (APN), leptin, chemerin, and visfatin) on the production of cytokines by unstimulated and poly(I:C)- and TNF-α-activated human primary bronchial epithelial cells (hBECs), (ii) the cells' expression of the APN receptors (AdipoR1 and AdipoR2), and (iii) the cells' production of APN.
METHODS METHODS
The hBECs were isolated from patients undergoing surgery for lung carcinoma. The cells were then cultured with human recombinant adipokines in the absence or presence of TNF-α or poly(I:C) for 24 h. Supernatant levels of cytokines (IL-6, CCL2, CCL5, CCL20, CXCL1, CXCL8) and APN were measured using ELISAs. The mRNA levels of AdipoR1 and AdipoR2 in hBECs were determined using a real-time quantitative PCR.
RESULTS RESULTS
Of the four adipokines tested, only APN significantly influenced the basal production and the TNF-α poly(I:C)-induced production of cytokines by hBECs. APN (3-30 µg.ml
CONCLUSIONS CONCLUSIONS
The APN concentrations are abnormally low in obese individuals, and this fall may contribute to the susceptibility to viral lung infections and the severity of these infections in obese individuals.

Identifiants

pubmed: 32132922
doi: 10.3389/fphar.2020.00056
pmc: PMC7040162
doi:

Types de publication

Journal Article

Langues

eng

Pagination

56

Informations de copyright

Copyright © 2020 Salvator, Grassin-Delyle, Naline, Brollo, Fournier, Couderc and Devillier.

Références

Biochem Biophys Res Commun. 1999 Apr 2;257(1):79-83
pubmed: 10092513
J Immunol. 2009 Nov 15;183(10):6489-99
pubmed: 19841182
J Allergy Clin Immunol. 2009 Aug;124(2):230-7, 237.e1-4
pubmed: 19539983
Respir Res. 2017 Apr 24;18(1):71
pubmed: 28438162
PLoS Pathog. 2011 Nov;7(11):e1002358
pubmed: 22072972
Clin Microbiol Rev. 2011 Jan;24(1):210-29
pubmed: 21233513
J Allergy Clin Immunol. 2017 Jun;139(6):1736-1751
pubmed: 28583446
J Biol Chem. 2016 Oct 14;291(42):22043-22052
pubmed: 27566543
Nat Rev Immunol. 2011 Feb;11(2):85-97
pubmed: 21252989
Br J Nutr. 2004 Sep;92(3):347-55
pubmed: 15469638
Rev Pneumol Clin. 2011 Sep;67(4):244-9
pubmed: 21920285
Ann N Y Acad Sci. 2014 Apr;1311:31-41
pubmed: 24517401
J Immunol. 2009 Jan 1;182(1):684-91
pubmed: 19109202
Thorax. 2009 Jan;64(1):26-32
pubmed: 18835960
J Allergy Clin Immunol. 2011 Sep;128(3):508-15.e1-2
pubmed: 21782230
Exp Ther Med. 2016 Dec;12(6):4168-4174
pubmed: 28105143
JCI Insight. 2018 Apr 19;3(8):
pubmed: 29669945
Pharmacol Res. 2018 Sep;135:25-36
pubmed: 30031171
Diabetes. 2005 Aug;54(8):2277-86
pubmed: 16046292
Circ J. 2017 Jun 23;81(7):920-928
pubmed: 28603178
Am J Physiol Lung Cell Mol Physiol. 2016 Aug 1;311(2):L255-69
pubmed: 27288489
Int J Biochem Cell Biol. 2013 Jun;45(6):1145-53
pubmed: 23500159
Cell Biol Int. 2009 Jan;33(1):19-30
pubmed: 18996492
N Engl J Med. 2017 Jul 6;377(1):13-27
pubmed: 28604169
Respir Res. 2017 Dec 13;18(1):208
pubmed: 29237464
Respir Med. 2012 May;106(5):651-60
pubmed: 22326605
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
J Allergy Clin Immunol. 2013 Sep;132(3):665-675.e8
pubmed: 23632299
J Biol Chem. 2009 Oct 2;284(40):27344-51
pubmed: 19654329
BMC Public Health. 2018 Feb 20;18(1):271
pubmed: 29458350
Peptides. 2013 Feb;40:34-41
pubmed: 23220445
Eur Respir J. 2015 May;45(5):1463-78
pubmed: 25792631
Expert Rev Respir Med. 2018 Sep;12(9):755-767
pubmed: 30056777
Lancet. 2017 Dec 16;390(10113):2627-2642
pubmed: 29029897
J Inflamm (Lond). 2008 Sep 22;5:15
pubmed: 18808711
PLoS One. 2010 Mar 15;5(3):e9694
pubmed: 20300571
J Immunol. 2011 May 1;186(9):5457-67
pubmed: 21430224
Anal Biochem. 1987 Apr;162(1):156-9
pubmed: 2440339
Front Immunol. 2018 Aug 10;9:1843
pubmed: 30147697
PLoS Med. 2011 Jul;8(7):e1001053
pubmed: 21750667

Auteurs

Hélène Salvator (H)

Laboratory of Research in Respiratory Pharmacology-UPRES EA220, UFR Sciences de la Santé Simone Veil, Université Paris-Saclay, Suresnes, France.
Department of Respiratory Diseases, Hôpital Foch, Suresnes, France.

Stanislas Grassin-Delyle (S)

Department of Respiratory Diseases, Hôpital Foch, Suresnes, France.
Mass Spectrometry Platform & INSERM UMR1173, UFR Sciences de la Santé Simone Veil, Université Versailles Saint Quentin en Yvelines, Université Paris-Saclay, Montigny-le-Bretonneux, France.

Emmanuel Naline (E)

Laboratory of Research in Respiratory Pharmacology-UPRES EA220, UFR Sciences de la Santé Simone Veil, Université Paris-Saclay, Suresnes, France.
Department of Respiratory Diseases, Hôpital Foch, Suresnes, France.

Marion Brollo (M)

Laboratory of Research in Respiratory Pharmacology-UPRES EA220, UFR Sciences de la Santé Simone Veil, Université Paris-Saclay, Suresnes, France.

Caroline Fournier (C)

Laboratory of Research in Respiratory Pharmacology-UPRES EA220, UFR Sciences de la Santé Simone Veil, Université Paris-Saclay, Suresnes, France.

Louis-Jean Couderc (LJ)

Laboratory of Research in Respiratory Pharmacology-UPRES EA220, UFR Sciences de la Santé Simone Veil, Université Paris-Saclay, Suresnes, France.
Department of Respiratory Diseases, Hôpital Foch, Suresnes, France.

Philippe Devillier (P)

Laboratory of Research in Respiratory Pharmacology-UPRES EA220, UFR Sciences de la Santé Simone Veil, Université Paris-Saclay, Suresnes, France.
Department of Respiratory Diseases, Hôpital Foch, Suresnes, France.

Classifications MeSH